Fig. 5
From: CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
Correlation of CA916798 with Gefitinib sensitivity in LUAD cells
A) Cell growth curves of parent and Gefitinib-resistant cells from PC9 and HCC827 measured via CCK8.
B) mRNA level of CA916798 in parent and Gefitinib-resistant cells from PC9 and HCC827 measured via qRT-PCR. ***P < 0.001
C) mRNA level of CA916798 in PC9 and PC9/GR (Gefitinib resistance) cells
D) mRNA level of CA916798 in PC9 and PC9/OR (Osimertinib resistance) cells
E and F) Cell growth curves with Gefitinib treatment and IC50 calculation of Gefitinib for PC9/Resistance (E) and HCC827/Resistance (F) cells stably transfected with control shRNA (shCtrl) or shRNA targeting CA916798 (shCA). **P < 0.01
G and H) Cell growth curves with Gefitinib treatment and IC50 calculation of Gefitinib for PC9 (G) and HCC (H) cells stably transfected with empty vector (Ctrl) or CA916798 (CA). **P < 0.01, ***P < 0.001